Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 04, 2015 10:48 AM ET


Company Overview of Celladon Corporation

Company Overview

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treat...

11988 El Camino Real

Suite 650

San Diego, CA 92130

United States

Founded in 2000

34 Employees





Key Executives for Celladon Corporation

Chief Executive Officer and Director
Age: 58
Total Annual Compensation: $417.5K
Vice President of Corporate Development & Investor Relations
Age: 43
Total Annual Compensation: $190.4K
Vice President of Corporate Operations
Age: 53
Total Annual Compensation: $216.3K
Vice President of Clinical Operations
Age: 52
Total Annual Compensation: $216.3K
Compensation as of Fiscal Year 2013.

Celladon Corporation Key Developments

Celladon Corporation - Special Call

To discuss negative results for CUPID2 trial of MYDICAR(R) in advanced heart failure

Celladon Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Celladon Corporation announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of USD 10,958,000 against USD 5,977,000 a year ago. Consolidated net loss was USD 11,341,000 against USD 6,179,000 a year ago. For the year, the company reported loss from operations of USD 33,018,000 against USD 19,964,000 a year ago. Consolidated net loss was USD 33,853,000 against USD 20,091,000 a year ago.

Celladon Seeks Acquisitions

Celladon Corporation (NasdaqGM:CLDN) announced an offering of 7 million of its common stocks and said that we intend to use the net proceeds from the sale of our common stock for general corporate purposes which may include clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our business, although we have no present commitments or agreements to make any such acquisitions or investments.

Similar Private Companies By Industry

Company Name Region
Clinical Data, Inc. United States
Immunotherapy Worldwide United States
Juniper Medical, Inc. United States
Neuro Bioscience Inc. United States
AdvanDx, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celladon Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at